These recalled products, packaged in a syringe, vial or eye dropper, were distributed across U.S. healthcare facilities from April 17 to Aug. 10.
The drugmaker issued the recall as a precautionary measure after the FDA identified issues during an inspection of the facility.
Bella Pharmaceuticals is informing customers of the recall and arranging for the return of all affected products.
More articles on supply chain:
Walmart follows Amazon, applies for aerial warehouse patent
7 must-reads for supply chain leaders this week
Mylan finalizes $465 million settlement with DOJ over EpiPen rebates
